Taletrectinib is now a preferred treatment for advanced ROS1-positive NSCLC, effective in first-line and subsequent therapies, especially for brain metastases. TRUST-I and TRUST-II trials showed high ...

Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new ...

With thoracic oncology in the middle of a combinatorial revolution—EGFR-targeted doublets and triplets, a maturing ...

Please provide your email address to receive an email when new articles are posted on . NCCN recommends osimertinib plus chemotherapy or lazertinib plus amivantamab-vmjw as first-line options for EGFR ...

Sequential therapy strategies in oncogene-driven NSCLC. This figure illustrates a proposed therapeutic decision-making pathway for patients with NSCLC who develop acquired resistance after initial ...

Targeted therapies and immunotherapies have transformed lung cancer treatment, especially for stage 4 patients, improving outcomes and quality of life. Early-stage lung cancer patients historically ...

The selection of a first-line treatment for patients with advanced EGFR-positive non-small cell lung cancer (NSCLC) has become increasingly complex in recent years with available options now including ...

Advanced NSCLC treatment lacks standardized next-line therapies, with significant variability in clinical practice observed. Median progression-free survival was 5.29 months, and overall survival was ...

The most widely studied targeted therapies for the third- and further-line treatment of NSCLC are EGFR inhibitors: gefitinib, erlotinib, cetuximab and afatinib (Table 3). The most important predictive ...

Dr. Joshua Reuss is back on the podcast to discuss the full update to the living guideline on stage IV NSCLC without driver alterations. He discusses the new evidence and how this impacts the latest ...